Michele Morales

CVS Health has delayed the inclusion of Gilead Sciences’ newest injectable for HIV prevention in its pharmacy benefit plans. This move might impact the availability of the innovative drug for patients. Recently authorized by regulatory bodies, the medication is regarded as a significant progress in HIV prevention, providing a more lasting option compared to current daily oral treatments.Gilead’s novel strategy focuses on both ease of use and effectiveness, aiming to enhance compliance for people vulnerable to HIV transmission. Instead of the usual pre-exposure prophylaxis (PrEP) pills that must be taken every day, this injection is given at extended intervals, lessening…

The United States Supreme Court has ruled in favor of implementing limitations on federal health research grants connected to diversity, equity, and inclusion (DEI) policies, a move that has ignited widespread debate across the academic and medical research communities. This decision supports previous measures introduced during Donald Trump’s administration, which sought to reduce funding for programs that required adherence to DEI standards as a condition for receiving grants.The court's decision is seen as a critical juncture in the ongoing debate on the allocation of federal money to research organizations. By maintaining these limitations, the decision could substantially alter the way…